4587 Stock Overview
A biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
PeptiDream Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥1,969.00 |
| 52 Week High | JP¥2,549.00 |
| 52 Week Low | JP¥1,039.00 |
| Beta | 0.65 |
| 1 Month Change | -5.38% |
| 3 Month Change | 28.40% |
| 1 Year Change | -16.39% |
| 3 Year Change | -58.68% |
| 5 Year Change | -65.70% |
| Change since IPO | 173.95% |
Recent News & Updates
PeptiDream Inc.'s (TSE:4587) 42% Price Boost Is Out Of Tune With Revenues
Apr 30
Is PeptiDream Inc. (TSE:4587) Trading At A 46% Discount?
Apr 29Shareholder Returns
| 4587 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | 1.7% | 4.0% | -1.2% |
| 1Y | -16.4% | -24.9% | 23.9% |
Return vs Industry: 4587 exceeded the JP Biotechs industry which returned -24.9% over the past year.
Return vs Market: 4587 underperformed the JP Market which returned 23.9% over the past year.
Price Volatility
| 4587 volatility | |
|---|---|
| 4587 Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 7.3% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in JP Market | 7.8% |
| 10% least volatile stocks in JP Market | 2.2% |
Stable Share Price: 4587's share price has been volatile over the past 3 months.
Volatility Over Time: 4587's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 603 | Patrick Crawford Reid | www.peptidream.com |
PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform that enables the production of non-standard peptide libraries for the identification of potent and selective macrocyclic peptide candidates, which then can be developed into peptide-based, small molecule-based, peptide-drug conjugate, and multi-functional peptide conjugates -based therapeutics and diagnostics. Its development pipeline include PD-L1 indicated for oncology and currently under Ph1 clinical phase development stage; PD-L1 BMS-986229 indicated for oncology and currently under Ph1 clinical phase development stage; CD38 BHV-1100 + NK Cells indicated for multiple myeloma and currently under Ph1 clinical phase development stage; S2-protein PA-001 indicated for COVID-19 and currently under Ph1 clinical phase development stage; GhR AZP-3813 indicated for acromegaly/NET and currently under Ph1 clinical phase development stage; Glypican-3 indicated for liver cancer and currently under preclinical development stage; Myostatin indicated for DMD/muscle disorders and currently under preclinical development stage; TfR indicated for neuromuscular disorders and currently under preclinical development stage; c-Kit indicated for allergic condition and currently under preclinical development stage; c-Met currently under preclinical development stage; and HA-protein indicated for influenza and currently under preclinical development stage.
PeptiDream Inc. Fundamentals Summary
| 4587 fundamental statistics | |
|---|---|
| Market cap | JP¥255.20b |
| Earnings (TTM) | JP¥2.44b |
| Revenue (TTM) | JP¥27.97b |
104.5x
P/E Ratio9.1x
P/S RatioIs 4587 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4587 income statement (TTM) | |
|---|---|
| Revenue | JP¥27.97b |
| Cost of Revenue | JP¥11.43b |
| Gross Profit | JP¥16.55b |
| Other Expenses | JP¥14.11b |
| Earnings | JP¥2.44b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 18.83 |
| Gross Margin | 59.16% |
| Net Profit Margin | 8.73% |
| Debt/Equity Ratio | 54.0% |
How did 4587 perform over the long term?
See historical performance and comparison